Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Credo Technology Group Holding Ltd (CRDO) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

Credo Technology Group Holding LtdTrade
Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

Credo Technology Group Holding Ltd vs Vertex Pharmaceuticals Incorporated — how do they compare? Credo Technology Group Holding Ltd trades at $256.76 (market cap $46.19B), while Vertex Pharmaceuticals Incorporated trades at $529.62 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.9× Credo Technology Group Holding Ltd's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Credo Technology Group Holding Ltd nearer its low. Which is the better fit depends on your goals.

CRDOVRTX
Market Cap
$46.19B$134.25B
Sector
TechnologyHealth
52-Week High
$302.52$529.65
52-Week Low
$87.81$376.62
Enterprise Value
$44.77B$128.37B

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Credo Technology Group Holding Ltd

Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.

Read more on CRDO

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Read more on VRTX